Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H22N2O8S2 |
Molecular Weight | 386.442 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)OCCC(=O)N1CCN(CC1)C(=O)CCOS(C)(=O)=O
InChI
InChIKey=NUKCGLDCWQXYOQ-UHFFFAOYSA-N
InChI=1S/C12H22N2O8S2/c1-23(17,18)21-9-3-11(15)13-5-7-14(8-6-13)12(16)4-10-22-24(2,19)20/h3-10H2,1-2H3
Piponulfan is neutral, difunctional alkylating derivative of piperazine. This agent was studied for their antineoplastic activity. Piposulfan has been found to be active against the following mouse tumors: sarcoma 180, carcinoma 755, and leukemia 1210. In patients with polycythemia piposulfan produced a response rate similar to that seen with pipobroman, busulfan, and triethylene melamine. However, piposulfan produces noticeably less toxicity than standard recommended doses of either busulfan or triethylene melamine. Various degrees of therapeutie remissions were seen in patients with malignant lymphomas, acute and chronic leukemia, multiple myeloma, adenocarcinomas, epidermoid carcinomas, and various types of sarcomas. The most common adverse reactions to piposulfan involved the hematopoietic (bone marrow depression) and gastrointestinal organs.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Midwest cooperative group evaluation of piposulfan (A-20968) in cancer. | 1967 May-Jun |
|
The treatment of lepromatous leprosy and erythema nodosum leprosum with the cytostatic drugs Ancyte and Vercyte. | 1967 Oct |
|
[Effect of piposulfan (ancyte) in malignant lymphomas and solid tumors]. | 1968 |
|
Effect of piposulfan (NSC-47774) on malignant lymphomas and solid tumors. | 1968 Apr |
|
Treatment of chronic granulocytic leukemia with piposulfan (NSC-47774). | 1969 Apr |
|
Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. | 1971 Jun 8 |
|
[Novel Bis-sulfonic Acid Esters with Cytostatic Activity (author's transl)]. | 1976 |
|
Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. | 1996 Feb |
|
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. | 1997 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5556760
Single dose - 200 mg/kg
Route of Administration:
Intraperitoneal
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C222
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1959
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
C107303
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
C1783
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL472696
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
m8864
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID80180713
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
SUB09878MIG
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
2608-24-4
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
17458
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
3475
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
47774
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
VY5DPN1TDU
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
100000082215
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY